Firefly Neuroscience(AIFF) Plunges 8.67% After Alzheimer's Breakthrough

Firefly Neuroscience(AIFF)跌8.67%。，The share price rose to its highest level since May 2025 today, with an intraday gain of 25.67% . The share price fell to its lowest level since April 2025 , with an intraday decline of 9.67%.

The strategy of buying AIFF shares after they reached a recent peak and holding for 1 week showed poor performance over the past 5 years. The annualized return was -12.4%, significantly underperforming the market. This indicates that relying on short-term price movements and holding onto stocks for a brief period is not a viable strategy, as it fails to capture the broader market's growth. Instead, a long-term perspective and periodic rebalancing are essential for better risk-adjusted returns in stock investments.

Firefly Neuroscience's stock experienced significant volatility on June 20, 2025, driven by a major breakthrough in Alzheimer's research. The company announced substantial advancements in objectively measuring subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia. This breakthrough involved combining EEG/ERP measures with volumetric brain MRI, with a particular focus on the left temporal lobe size, which has been shown to correlate with cognitive issues. This innovative approach is expected to enhance diagnostic certainty and facilitate earlier detection and intervention for Alzheimer's patients.

In addition to the research breakthrough, Firefly Neuroscience also made a strategic acquisition. The company acquired Evoke Neuroscience for $6 million, which is anticipated to further strengthen their research capabilities and market position. This acquisition is likely to contribute to the company's long-term growth and competitiveness in the neuroscience field.